Study identifier:D5241C00001
ClinicalTrials.gov identifier:NCT04039113
EudraCT identifier:2019-001363-67
CTIS identifier:N/A
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)
Chronic obstructive pulmonary disease (COPD)
Phase 2
No
-
All
337
Interventional
40 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Feb 2024 by AstraZeneca
AstraZeneca
Amgen
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: Tezepelumab Tezepelumab, SC, Q4W | Biological/Vaccine: Tezepelumab Tezepelumab subcutaneous injection Other Name: Tezepelumab |
Placebo Comparator: Matching Placebo Matching placebo, SC, Q4W | Other: Placebo Placebo subcutaneous injection |